Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 65.6%

Neg 0% Neu 0% Pos 65.6%

Baird analyst Wesley Golladay maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $22 to $23.